Melior Pharmaceuticals Announces Execution of License Agreement for Armesocarb by Adhera Therapeutics
EXTON, PA — Melior Pharmaceuticals announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc . (OTCPK: ATRX) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).
Melior Pharmaceuticals Announces Execution of License Agreement for Armesocarb by Adhera Therapeutics Read More